GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lucira Health Inc (OTCPK:LHDXQ) » Definitions » PE Ratio (TTM)

Lucira Health (Lucira Health) PE Ratio (TTM) : At Loss (As of May. 16, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lucira Health PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-05-16), Lucira Health's share price is $0.0001. Lucira Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $-3.58. Therefore, Lucira Health's PE Ratio (TTM) for today is At Loss.


The historical rank and industry rank for Lucira Health's PE Ratio (TTM) or its related term are showing as below:

LHDXQ' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: At Loss   Max: At Loss
Current: At Loss



LHDXQ's PE Ratio (TTM) is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 29.3 vs LHDXQ: At Loss

Lucira Health's Earnings per Share (Diluted) for the three months ended in Sep. 2022 was $-3.15. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $-3.58.

As of today (2024-05-16), Lucira Health's share price is $0.0001. Lucira Health's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2022 was $-3.58. Therefore, Lucira Health's PE Ratio without NRI for today is At Loss.

Lucira Health's EPS without NRI for the three months ended in Sep. 2022 was $-3.15. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2022 was $-3.58.

Lucira Health's EPS (Basic) for the three months ended in Sep. 2022 was $-3.15. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2022 was $-3.56.


Lucira Health PE Ratio (TTM) Historical Data

The historical data trend for Lucira Health's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucira Health PE Ratio (TTM) Chart

Lucira Health Annual Data
Trend Dec18 Dec19 Dec20 Dec21
PE Ratio (TTM)
N/A N/A N/A At Loss

Lucira Health Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Lucira Health's PE Ratio (TTM)

For the Medical Devices subindustry, Lucira Health's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lucira Health's PE Ratio (TTM) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lucira Health's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Lucira Health's PE Ratio (TTM) falls into.



Lucira Health PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Lucira Health's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=0.0001/-3.580
=At Loss

Lucira Health's Share Price of today is $0.0001.
Lucira Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.58.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Lucira Health  (OTCPK:LHDXQ) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Lucira Health PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Lucira Health's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Lucira Health (Lucira Health) Business Description

Traded in Other Exchanges
N/A
Address
1412 62nd Street, Emeryville, CA, USA, 94608
Lucira Health Inc is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. It has developed a testing platform that produces high-complexity-laboratory-accurate molecular testing in a single-use and user-friendly test kit that is powered by two AA batteries and fit in the palm of a hand. The company's initial focus is within respiratory diseases, and initially for COVID-19 and influenza Types A and B indications.
Executives
Anthony Joseph Allen officer: Chief Operations Officer 1412 62ND STREET, EMERYVILLE CA 94608
Epq Llc, Lcovd Safe Ps other: Less than 10% owner 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Chad Boeding other: CEO of 10% owner ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Epiq Capital Group, Llc 10 percent owner ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Epq Llc, Lcovd Ps 10 percent owner 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Lflu Ps other: Less than 10% owner 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Ltest Ps other: Less than 10% Owner 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Richard Clavano Narido officer: Interim CFO 12 HANSEN CT, MORAGA CA 94556
Ghazi Kashmolah officer: Ex. VP &Chief Quality Officer 1412 62ND STREET, EMERYVILLE CA 94608
Kevin Walter Collins officer: Chief Revenue Officer C/O LUCIRA HEALTH, INC., 1412 62ND STREET, EMERYVILLE CA 94608
Dan George officer: CFO and Treasurer 1412 62ND STREET, EMERYVILLE CA 94608
Erik T. Engelson director, officer: President and Chief Executive 1412 62ND STREET, EMERYVILLE CA 94608
Debkishore Mitra director, officer: Chief Technology Officer 1412 62ND STREET, EMERYVILLE CA 94608
Tamanna Prashar officer: Vice President 1412 62ND STREET, EMERYVILLE CA 94608
Alison Mccauley director C/O LUCIRA HEALTH, INC., 1412 62ND STREET, EMERYVILLE CA 94608